Answers are grounded in this paper and cite their sources.
Gemcitabine, 2'-deoxy-2',2'-difluorocytidine, is currently prescribed against a number of cancers. Here we report a linear synthesis of gemcitabine with a high-yielding direct conversion of 3,5-di-O-benzoyl-2-deoxy-2,2-difluororibose into the corresponding glycosyl urea as the key step, followed by conventional conversion to the cytosine base via the uracil derivative. The process proceeded with modest anomeric selectivity.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: